Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Lisa Brents to Humans

This is a "connection" page, showing publications Lisa Brents has written about Humans.

 
Connection Strength
  
 
 
0.256
  
  1. Tobacyk J, Brents LK. Response to article - alternative interpretation of "there is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome". J Matern Fetal Neonatal Med. 2023 12; 36(1):2183469.
    View in: PubMed
    Score: 0.038
  2. Tobacyk J, Parks BJ, Salazar P, Coward LU, Berquist MD, Gorman GS, Brents LK. Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome. Drug Alcohol Depend. 2023 08 01; 249:110832.
    View in: PubMed
    Score: 0.037
  3. Tobacyk J, Parks BJ, Lovelady N, Brents LK. Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom. Int J Drug Policy. 2022 10; 108:103817.
    View in: PubMed
    Score: 0.035
  4. Brents LK, James GA, Cisler JM, Kilts CD. Personality variables modify the relationship between childhood maltreatment history and poor functional outcomes. Psychiatry Res. 2018 10; 268:229-237.
    View in: PubMed
    Score: 0.026
  5. Brents LK. Marijuana, the Endocannabinoid System and the Female Reproductive System. Yale J Biol Med. 2016 06; 89(2):175-91.
    View in: PubMed
    Score: 0.023
  6. Brents LK, Tripathi SP, Young J, James GA, Kilts CD. The role of childhood maltreatment in the altered trait and global expression of personality in cocaine addiction. J Psychiatr Res. 2015 May; 64:23-31.
    View in: PubMed
    Score: 0.021
  7. Brents LK, Prather PL. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev. 2014 Feb; 46(1):72-85.
    View in: PubMed
    Score: 0.019
  8. Brents LK, Medina-Bolivar F, Seely KA, Nair V, Bratton SM, Nopo-Olazabal L, Patel RY, Liu H, Doerksen RJ, Prather PL, Radominska-Pandya A. Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica. 2012 Feb; 42(2):139-56.
    View in: PubMed
    Score: 0.017
  9. Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol. 2013 Jun 01; 269(2):100-8.
    View in: PubMed
    Score: 0.005
  10. Madadi NR, Penthala NR, Brents LK, Ford BM, Prather PL, Crooks PA. Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors. Bioorg Med Chem Lett. 2013 Apr 01; 23(7):2019-21.
    View in: PubMed
    Score: 0.005
  11. Safe SH, Prather PL, Brents LK, Chadalapaka G, Jutooru I. Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anticancer Agents Med Chem. 2012 Dec; 12(10):1211-20.
    View in: PubMed
    Score: 0.004
  12. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 2012 Nov; 40(11):2174-84.
    View in: PubMed
    Score: 0.004
  13. Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct; 63(5):905-15.
    View in: PubMed
    Score: 0.004
  14. Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther. 2012 Jul; 11(7):1421-31.
    View in: PubMed
    Score: 0.004
  15. Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol. 2012 Apr 16; 25(4):825-7.
    View in: PubMed
    Score: 0.004
  16. Koryakina Y, Jones SM, Cornett LE, Seely K, Brents L, Prather PL, Kofman A, Kurten RC. Effects of the ?-agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of ?2-adrenergic receptors with N-terminal polymorphisms. Cell Biol Int. 2012; 36(12):1171-83.
    View in: PubMed
    Score: 0.004
  17. Ajmo JM, Bailey LA, Howell MD, Cortez LK, Pennypacker KR, Mehta HN, Morgan D, Gordon MN, Gottschall PE. Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice over-expressing APPsw. J Neurochem. 2010 May; 113(3):784-95.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.